Reduction of Cardiovascular Risk through Angiotensin II Type 1 Receptor Antagonism: Focus on Olmesartan Medoxomil

By Enrico Agabiti Rosei  

High Blood Pressure & Cardiovascular Prevention, Vol. 15, Iss. 4, 2008-01 ,pp. : 231-243

Adis International

Access to resources Recommend Favorite

The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice

By Masamune Atsushi   Hamada Shin   Kikuta Kazuhiro   Takikawa Tetsuya   Miura Shin   Nakano Eriko   Shimosegawa Tooru  

Scandinavian Journal of Gastroenterology, Vol. 48, Iss. 5, 2013-05 ,pp. : 602-609

Informa Healthcare

Access to resources Recommend Favorite

Ambulatory Blood Pressure Monitoring to Assess the Comparative Efficacy and Duration of Action of a Novel New Angiotensin II Receptor Blocker - Telmisartan

By Neutel Joel M.  

Blood Pressure, Vol. 10, Iss. 1, 2001-02 ,pp. : 27-32

Informa Healthcare

Access to resources Recommend Favorite

Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension

By TRENKWALDER P.   DAHL K.   LEHTOVIRTA M.   MULDER H.  

Blood Pressure, Vol. 9, Iss. 1, 2000-05 ,pp. : 57-57

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin II receptor blocker combinations: From guidelines to clinical practice

By Narkiewicz Krzysztof  

Blood Pressure, Vol. 21, Iss. 2, 2012-04 ,pp. : 73-81

Informa Healthcare

Access to resources Recommend Favorite